133 related articles for article (PubMed ID: 15293789)
21. Leukemic transformation by the v-ErbA oncoprotein entails constitutive binding to and repression of an erythroid enhancer in vivo.
Ciana P; Braliou GG; Demay FG; von Lindern M; Barettino D; Beug H; Stunnenberg HG
EMBO J; 1998 Dec; 17(24):7382-94. PubMed ID: 9857194
[TBL] [Abstract][Full Text] [Related]
22. The effect of oncoprotein v-erbA on thyroid hormone-regulated genes in hepatocytes and their potential role in hepatocellular carcinoma.
Ventura-Holman T; Mamoon A; Subauste MC; Subauste JS
Mol Biol Rep; 2011 Feb; 38(2):1137-44. PubMed ID: 20571909
[TBL] [Abstract][Full Text] [Related]
23. A novel cis element mediating ligand-independent activation by c-ErbA: implications for hormonal regulation.
Saatcioglu F; Deng T; Karin M
Cell; 1993 Dec; 75(6):1095-105. PubMed ID: 7903219
[TBL] [Abstract][Full Text] [Related]
24. Two silencing sub-domains of v-erbA synergize with each other, but not with RXR.
Martin B; Renkawitz R; Muller M
Nucleic Acids Res; 1994 Nov; 22(23):4898-905. PubMed ID: 7800478
[TBL] [Abstract][Full Text] [Related]
25. Thyroid hormone receptor-beta mutants associated with generalized resistance to thyroid hormone show defects in their ligand-sensitive repression function.
Piedrafita FJ; Ortiz MA; Pfahl M
Mol Endocrinol; 1995 Nov; 9(11):1533-48. PubMed ID: 8584031
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the DNA binding specificity and function of v-ErbA and thyroid hormone receptor alpha 1.
Subauste JS; Koenig RJ
J Biol Chem; 1995 Apr; 270(14):7957-62. PubMed ID: 7713893
[TBL] [Abstract][Full Text] [Related]
27. Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT.
Matsushita A; Misawa H; Andoh S; Natsume H; Nishiyama K; Sasaki S; Nakamura H
J Endocrinol; 2000 Dec; 167(3):493-503. PubMed ID: 11115777
[TBL] [Abstract][Full Text] [Related]
28. A domain containing leucine-zipper-like motifs mediate novel in vivo interactions between the thyroid hormone and retinoic acid receptors.
Forman BM; Yang CR; Au M; Casanova J; Ghysdael J; Samuels HH
Mol Endocrinol; 1989 Oct; 3(10):1610-26. PubMed ID: 2558297
[TBL] [Abstract][Full Text] [Related]
29. Structure-function analysis of the Rev-erbA and RVR ligand-binding domains reveals a large hydrophobic surface that mediates corepressor binding and a ligand cavity occupied by side chains.
Renaud JP; Harris JM; Downes M; Burke LJ; Muscat GE
Mol Endocrinol; 2000 May; 14(5):700-17. PubMed ID: 10809233
[TBL] [Abstract][Full Text] [Related]
30. Constitutive transactivation by the thyroid hormone receptor and a novel pattern of activity of its oncogenic homolog v-ErbA in Xenopus oocytes.
Nagl SB; Nelson CC; Romaniuk PJ; Allison LA
Mol Endocrinol; 1995 Nov; 9(11):1522-32. PubMed ID: 8584030
[TBL] [Abstract][Full Text] [Related]
31. Recruitment of the oncoprotein v-ErbA to aggresomes.
Bondzi C; Brunner AM; Munyikwa MR; Connor CD; Simmons AN; Stephens SL; Belt PA; Roggero VR; Mavinakere MS; Hinton SD; Allison LA
Mol Cell Endocrinol; 2011 Jan; 332(1-2):196-212. PubMed ID: 21075170
[TBL] [Abstract][Full Text] [Related]
32. The lack of transcriptional activation of the v-erbA oncogene is in part due to a mutation present in the DNA binding domain of the protein.
de Verneuil H; Metzger D
Nucleic Acids Res; 1990 Aug; 18(15):4489-97. PubMed ID: 1975094
[TBL] [Abstract][Full Text] [Related]
33. The orphan receptor TAK1 acts as a repressor of RAR-, RXR- and T3R-mediated signaling pathways.
Hirose T; Apfel R; Pfahl M; Jetten AM
Biochem Biophys Res Commun; 1995 Jun; 211(1):83-91. PubMed ID: 7779113
[TBL] [Abstract][Full Text] [Related]
34. Multiple mutations contribute to repression by the v-Erb A oncoprotein.
Lee S; Privalsky ML
Oncogene; 2005 Oct; 24(45):6737-52. PubMed ID: 16007162
[TBL] [Abstract][Full Text] [Related]
35. The function of retinoid X receptors on negative thyroid hormone response elements.
Takeda T; Nagasawa T; Miyamoto T; Hashizume K; DeGroot LJ
Mol Cell Endocrinol; 1997 Apr; 128(1-2):85-96. PubMed ID: 9140079
[TBL] [Abstract][Full Text] [Related]
36. Divergent dimerization properties of mutant beta 1 thyroid hormone receptors are associated with different dominant negative activities.
Hao E; Menke JB; Smith AM; Jones C; Geffner ME; Hershman JM; Wuerth JP; Samuels HH; Ways DK; Usala SJ
Mol Endocrinol; 1994 Jul; 8(7):841-51. PubMed ID: 7984146
[TBL] [Abstract][Full Text] [Related]
37. Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erbA yields a chromatin infrastructure-dependent transcriptional repression pathway.
Urnov FD; Yee J; Sachs L; Collingwood TN; Bauer A; Beug H; Shi YB; Wolffe AP
EMBO J; 2000 Aug; 19(15):4074-90. PubMed ID: 10921888
[TBL] [Abstract][Full Text] [Related]
38. Structural features of thyroid hormone response elements that increase susceptibility to inhibition by an RTH mutant thyroid hormone receptor.
Zavacki AM; Harney JW; Brent GA; Larsen PR
Endocrinology; 1996 Jul; 137(7):2833-41. PubMed ID: 8770904
[TBL] [Abstract][Full Text] [Related]
39. Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency.
Meier CA; Parkison C; Chen A; Ashizawa K; Meier-Heusler SC; Muchmore P; Cheng SY; Weintraub BD
J Clin Invest; 1993 Oct; 92(4):1986-93. PubMed ID: 8408652
[TBL] [Abstract][Full Text] [Related]
40. Thyroid hormone receptor, v-ErbA, and chromatin.
Wolffe AP; Collingwood TN; Li Q; Yee J; Urnov F; Shi YB
Vitam Horm; 2000; 58():449-92. PubMed ID: 10668407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
